Supplemental Figure 5

Aug 15, 2014

10 likes | 122 Views

Supplemental Figure 5. A. MTLn3 GFP-CXCL12. MTLn3 GFP-pQCXIP. C. B. ***. CXCR4. IgG. % of max. BMM Chemotaxis to CXCL12. % of max. CXCR4-PE. CXCR4-PE. IgG. CXCR4. B.

Share Presentation

Embed Code

Link

mtln3 gfp
cxcr4-pe cxcr4-pe igg cxcr4
figure
bmm chemotaxis
pqcxip c

thora

Download Presentation

Supplemental Figure 5

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

Supplemental Figure 5 A. MTLn3 GFP-CXCL12 MTLn3 GFP-pQCXIP C. B. *** CXCR4 IgG % of max BMM Chemotaxis to CXCL12 % of max CXCR4-PE CXCR4-PE IgG CXCR4 B.

Supplemental figure 4

A. B. C. D. Supplemental figure 4. Supplemental Figure S4. Kinetics of total IFN γ + (A), IL-2+ (B) and TNFa+ (C) CD4+ and IFN γ + (D) CD8+ T-cell responses in KTRs during the clinical course of BKV re-activation

163 views • 2 slides

Supplemental Figure 1

2500. 2000. 1500. 1000. 500. Supplemental Figure 1. CS-0777 product [ ng/mL ･ mg protein ]. 0. #1. #2. #3. #4. #5. Human specimen number. Supplemental figure 1. Examination of individual specificity of CS-0777-P phosphatase activity

259 views • 7 slides

Supplemental Figure 1

Supplemental Figure 1. A. Mock. MOI-100. MOI-10. 0.5%. 79.7%. 21.8%. CD3 PerCP. NY-ESO-1 Tetramer PE. B. C. Supplemental Figure 2. A. Thymus. L Humerus. R Humerus. Muscle. L Femur. R Femur. C. B. P < 0.0001. Supplemental Figure 3. A. B.

164 views • 3 slides

Supplemental Figure 2.

MS/MS spectrum of a single peptide that identified a protein. The b and y ion series, ion scores, and ranking in the Mascot search were manually inspected. Supplemental Figure 2. Spot 6069. Spot 5331. Spot 3696. Spot 5018. Spot 4068.

217 views • 6 slides

Supplemental Figure 4

Supplemental Figure 4.

73 views • 1 slides

Supplemental Figure 1

A. B. C. D. E. F. Supplemental Figure 1. Supplemental Figure S1. Incidence of CD4+ IFN γ (A) , IL-2 (C) and TNFa (E) responders and magnitude of total IFN γ + (B), IL-2+ (D) and TNFa+ (F) CD4+ T-cell responses in different patient groups

154 views • 6 slides

Supplemental Figure 1

Supplemental Figure 1. Patient 2. Supplemental Figure 2. Patient:. 1. 2. 3. No cDNA. No cDNA. No cDNA. - Ac. - Ac. - Ac. - Ac. - Ac. - Ac. IgG. IgG. IgG. IgG. IgG. IgG. IgA. IgA. IgA. IgA. IgA. IgA. Patient:. 4. 5. 6. No cDNA. - Ac. - Ac. - Ac. - Ac.

108 views • 4 slides

Supplemental Figure 1

Supplemental Figure 1. c. . MGC-803. 4. 4. 3. 3. miR-185 levels (fold). 40. TUNEL positive cells (%). 2. 2. . 1. 1. 20. 0. 0. . 60. 60. 0. –. CDDP(30 m M). +. +. +. TUNEL positive cells (%). 40. 40. . –. –. –. miR-185 AntagomiR. +. –. –. –.

80 views • 1 slides

Supplemental Figure 5

Trastuzumab-treated. Control-treated. A. MDA-MB-453. 14.2%. 10.7%. DEAB-inhibited. DEAB-inhibited. B. JIMT-1. 5.2%. 5.4%. DEAB-inhibited. DEAB-inhibited. C. Sum159-HER2. 7.1%. 36%. DEAB-inhibited. DEAB-inhibited. Trastuzumab-treated. Control-treated. D. Supplemental Figure 5.

136 views • 1 slides

Supplemental Figure 1

Supplemental Figure 1. Supplemental Figure 1 . Southern of AtplaIVC-1

87 views • 1 slides

Supplemental Figure 4

Supplemental Figure 4. a. 1000, 2000, 4000, 8000 cells/well into 96 well dish. 10, 20, 40, 80 cells/well into 96 well dish. R.L.U. measurement. R.L.U. measurement. CellTiter-Glo. CellTiter-Glo. 10% FBS DMEM. 10% FBS DMEM. 7 days. 6 hr. co llagen concentration.

103 views • 1 slides

Supplemental Figure.

Supplemental Figure. Legend:

92 views • 3 slides

Supplemental Figure 5

Supplemental Figure 5.

73 views • 1 slides

Supplemental Figure 5

Supplemental Figure 5. p <0.05. p =0.05. a. b. p <0.05. p <0.05. p <0.05. p <0.05. c. Muscle. d. Liver. + - + - UCP3. p <0.01. UCP3. SDH. p <0.05.

86 views • 1 slides

Vernin et al., supplemental Figure 5

PI positive cells (%). Vernin et al., supplemental Figure 5.

111 views • 1 slides

Supplemental Figure S 5

A. B. Supplemental Figure S 5.

75 views • 1 slides

Supplemental Figure 2

Supplemental Figure 2.

88 views • 1 slides

Supplemental Figure 1.

Supplemental Figure 1. Immunohistochemistry for Hic-5 in human small intestine. In the epithelial cells, Hic-5 appears to be localized primarily in the apical portion of the epithelium.

85 views • 1 slides

Supplemental Figure 1

Supplemental Figure 1.

85 views • 1 slides

Supplemental Figure S1

Supplemental Figure S1.

477 views • 40 slides

Supplemental Figure 1

B. Axonal Blebbing. t = 0 min. t = 0 min. t = 5 min. t = 5 min. t = 10 min. t = 10 min. t = 15 min. t = 15 min. t = 20 min. t = 20 min. A. Growth Cone Ruffling. D. Average Positive Particle Velocity Histogram. C. WGA Kymograph (4 hr incubation). 0 min. Time. *. 20 min.

200 views • 2 slides

Supplemental Figure 1

Supplemental Figure 1. 0. LNCaP/Luc/PHB-siRNA. b. No Dox No DHT. No Dox No DHT. No Dox + DHT. *. No Dox + DHT. 20. 1.4. PHB-RNAi No DHT. PHB-RNAi No DHT. *. PHB-RNAi + DHT. PHB-RNAi + DHT. 1.2. *. 15. 1. *. Fold Enrichment of AR. 0.8. Fold Enrichment of PHB. 10. 0.6. 0.4.

111 views • 9 slides

More Related